Search Results

1 - 10 of 417 items :

  • "proteomics" x
Clear All

(5 Pt. 1): 470-485. 9. Oliva R, de Mateo S, Estanyol JM. Sperm cell proteomics. Proteomics. 2009; 9(4): 1004-1017. 10. de Mateo S, Castillo J, Estanyol JM, Ballescà JL, Oliva R. Proteomic characterization of the human sperm nucleus. Proteomics. 2011; 11(13): 2714-2726. 11. Martinez-Heredia J, Estanyol JM, Ballesca JL, Oliva R. Proteomic identification of human sperm proteins. Proteomics. 2006; 6(15): 4356-4369. 12. Baker MA, Reeves G, Hetherington L, Muller J, Baur I, Aitken RJ. Identification of gene products present in Triton X-100 soluble and insoluble fractions of

References Agrawal GK, Yonekura M, Iwahashi Y, Iwahashi H, Rakwal R (2005) J. Chromatogr. B. 815: 109-123. Abhilash M (2009) The Internet Journal of Genomics and Proteomics. 4: DOI: 10.5580/1787. Albert R (2007) Plant Cell 19: 3327-3338. Basha SM, Mazhar H, Vasanthaiah HK (2010) Appl. Biochem. Biotechnol. 160:932-44. Buiatti M, Bennici A (1970) Rend. Accad. Naz. Lincei. 48: 261-269. Castro AJ, Carapito C, Zorn N, Magne C, Leize E, Van Dorsselaer A (2005) J. Exp. Bot. 56:2783-95. Čarna M, Repka V, Šturdik E (2011) Agriculture 57: 129-136. da Silva FG, Iandolino A

INTRODUCTION The use of proteomics to track relative protein expression is becoming a common approach to understand how an organism responds on a molecular level to a variety of environmental conditions or genetic mutations. Historically, a transcriptomic approach has been used to understand changes in plant gene expression during spaceflight ( Beaulieu et al., 2013 ; Paul et al., 2005 ; Paul et al., 2012 ; Paul et al., 2013 ; Salmi and Roux 2008 ; Salmi et al., 2011a ; Salmi et al., 2011b ). This is an attractive approach because vast quantities of data

, antiparasitic, and antiobesity properties [ 9 ]. Central to these properties is a secondary xanthone metabolite known as a-mangostin (AM) [ 10 ]. Studies we conducted in vivo found that treatment with AM could reduce thioacetamide (TAA)-induced hepatic fibrosis [ 11 ]. Another study suggested that AM could attenuate lipid peroxidation, reduce proinflammatory mediators, inhibit the activities of hepatic stellate cells, and reduce portal blood pressure in rat models of fibrosis [ 12 ]. However, to our knowledge, no proteomic investigation of the effects of AM on renal fibrosis

initiative cohort. Dement Geriatr Cogn Disord. 2015; 39(3-4):154-66. DOI: 10.1159/000368982. 15. Gupta VB, Laws SM, Villemagne VL, Ames D, Bush AI, Ellis KA, et al. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology. 2011 Mar 22; 76(12):1091-8. DOI: 10.1212/WNL.0b013e318211c352. 16. Guo LH, Alexopoulos P, Wagenpfeil S, Kurz A, the Alzheimer’s Disease Neuroimaging Inititative, Perneczcky R. Plasma proteomics for the identification of Alzheimer’s disease. Alzheimer Dis Assoc Disord. 2013 Oct-Dec; 27(4):10. DOI: 10.1097/ WAD.0b013e31827b60d

, Kalyanaraman B. Analysis of proteome changes in doxorubicintreated adult rat cardiomyocyte. J Proteomics. 2011; 74:683-97. 6. Kotamraju S, Konorev EA, Joseph J, Kalyanaraman B. Doxorubicin induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem. 2000; 275:33585-92. 7. Zhang B, Wang M, Yang Y, Wang Y, Pang X, Su Y, et al. ERp29 is a radiation-responsive gene in IEC-6 cell. J Radiat Res (Tokyo). 2008; 49:587-96. 8. Shan YX, Liu TJ, Su HF, Samsamshariat A, Mestril R

(1): 35-43. 20. Goo YA, Goodlett DR. Advances in proteomic prostate cancer biomarker discovery. J Proteomics. 2010; 73(10): 1839-1850. 21. Pin E, Fredolini C, Petricoin EF, 3rd. The role of proteomics in prostate cancer research: biomarker discovery and validation. Clin Biochem. 2013; 46(6): 524-538. 22. Fredolini C, Liotta LA, Petricoin EF. Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy. Crit Rev Clin Lab Sci. 2010; 47(3): 125-138. 23. Garbis SD, Townsend PA. Proteomics of human prostate cancer biospecimens: the

References Thongboonkerd V. Recent progress in urinary proteomics. Proteomics Clin Appl 2007; 1: 780-91. Fliser D, Novak J, Thongboonkerd V, Argilés A, Jankowski V, Girolami MA, Jankowski J, Mischak H. Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol 2007; 18 (4): 1057-71. Decramer S, Gonzalez de Peredo A, Breuil B, Mischak H, Monsarrat B, Bascands JL, Schanstra JP. Urine in clinical proteomics. Mol Cell Proteomics 2008; 7 (10): 1850-62. Vlahou A, Schanstra J, Frokiaer J, El NM, Spasovski G, Mischak H, Domon B, Allmaier G

Proceedings of the MACPROGEN Final Conference held at Ohrid, Republic of Macedonia, March 29-April 1 2012 INTRODUCTION The “National Reference Centre for Genomics and Proteomics” (MACPROGEN) was financed by the European Commission within the FP7 Capacities Work Program for a period of 3 years, starting April 1 2009. The MACPROGEN project aimed at up- grading and improving the capacity of the Research Centre for Genetic Engineering and Biotechnology (RCGEB) “Georgi D. Efremov,” Macedonian Academy of Sciences and Arts (MASA), Skopje, Republic of Macedonia

the changes in blood proteins in early atherosclerosis will help identify new candidate biomarkers for the detection of this disease before the onset of clinical manifestations. The proteomic analysis allows researchers to overcome the difficulties associated with a wide concentration range of proteins in the blood and their post-translational modifications. For early diagnosis of the disease, special attention is paid to acute phase proteins and proteins involved in the implementation of an immune response. Proteins of the complement system, which is the most